FDA Archives - Page 85 of 220

4 minute read

MapKure, BeiGene And SpringWorks Present Clinical Data On BGB-3245, A Selective Next-Generation B-RAF Inhibitor, In Adult Patients With Advanced Or Refractory Solid Tumors At The American Association For Cancer Research Annual Meeting 2023

April 17, 2:31 PM

MapKure, LLC, BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)))), and SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), today announced that they will present updated clinical data from the Phase 1a/1b study of

BGNE

3 minute read

Vincerx Pharma Presents Preclinical Data On Novel Small Molecule Drug Conjugates At The American Association For Cancer Research Annual Meeting 2023

By Happy Mohamed

April 17, 1:37 PM

Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented a poster of preclinical

VINC

3 minute read

Anixa Biosciences And Cleveland Clinic Present Data For Phase 1 Study Of Breast Cancer Vaccine

By Happy Mohamed

April 17, 1:36 PM

Immune responses were observed at all dose levels SAN JOSE, Calif., April 17, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment and

ANIX

3 minute read

Caribou Biosciences Presents New Preclinical Data On CB-012, An Allogeneic Anti-CLL-1 CAR-T Cell Therapy, At The 2023 AACR Annual Meeting

By Happy Mohamed

April 17, 1:31 PM

-- CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML xenograft models -- -- CB-012 IND-enabling studies ongoing; IND submission in r/r AML planned for

CRBU

3 minute read

Harpoon Therapeutics Presents Data For New ProTriTAC Development Candidates In TROP2- And ITGB6-Expressing Solid Tumors At AACR 2023

By Happy Mohamed

April 17, 1:31 PM

Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today presented preclinical data on two new development candidates from the proprietary

HARP

3 minute read

Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity In Previously Treated Head And Neck Squamous Cell Carcinoma

By Happy Mohamed

April 17, 10:17 AM

- 37% overall response rate (ORR) observed in 43 evaluable patients - 6 months median duration of response as of Feb. 1, 2023 data cutoff date - End-of-phase meeting with U.S. Food & Drug Administration

MRUS

4 minute read

Allogene Therapeutics Presents Interim Phase 1 Data On ALLO-316 In Renal Cell Carcinoma At The American Association Of Cancer Research Annual Meeting

By Happy Mohamed

April 17, 10:17 AM

Data Provide Proof-of-Concept for an Allogeneic Anti-CD70 CAR T Candidate in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint Inhibitor and VEGF-Targeting Therapy Single Infusion

ALLO

3 minute read

Elevation Oncology Presents EO-3021 Preclinical Proof-Of-Concept Data And Highlights A Clinical Case Study In Claudin 18.2-Expressing Cancers At AACR 2023

By Happy Mohamed

April 17, 10:16 AM

EO-3021 demonstrated anti-tumor activity in preclinical models expressing varying levels of Claudin 18.2 EO-3021 induced a confirmed partial response in a patient with metastatic gastric cancer Company is on track to

ELEV

5 minute read

Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023

By Happy Mohamed

April 17, 9:09 AM

Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types including platinum-resistant ovarian cancer Company anticipates sharing clinical data from ovarian chemotherapy combination

ZNTL

2 minute read

XBiotech Announces First Subject Enrollment In Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke

By Happy Mohamed

April 17, 9:05 AM

XBiotech Inc. (NASDAQ:XBIT) has enrolled the first subject in a randomized, open-label, placebo-controlled dose escalation clinical study to evaluate safety and pharmacokinetics of Hutrukin. Hutrukin is

XBIT